Journal article · 2016 · Open access

761. Targeted Killing of HIV Infected Cells Using CCR5-Disrupted Anti-HIV-CAR T Cells

Guillermo S. Romano Ibarra, Malika R. Hale, Karen Sommer, Iram Khan, Jaya Sahni, Christopher W. Peterson, Hans‐Peter Kiem, Jordan Jarjour, Alexander Astrakhan, Andrew M. Scharenberg, David J. Rawlings, Thor A. Wagner

Molecular Therapy, 24, S301 · Published 1 May 2016 · DOI 10.1016/s1525-0016(16)33569-9

Open PDFView at the publisherCite this paper

In brief

“761. Targeted Killing of HIV Infected Cells Using CCR5-Disrupted Anti-HIV-CAR T Cells” is a 2016 journal article by Guillermo S. Romano Ibarra and 11 co-authors, published in Molecular Therapy. OpenAlex counts 2 citations as of 19 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Molecular Therapy.

Citations
2
Most cited in
2023 (1)
Authors
12

Abstract

A cure for HIV remains an important treatment goal for 30 million HIV-infected individuals worldwide. Long term control of HIV following a single treatment will require a mechanism to eradicate the latent reservoir of HIV infected cells that are capable of reactivating. A previous phase II clinical trial using an anti-HIV chimeric antigen receptor (αHIV-CAR) targeting the CD4-binding site on HIV envelope was partially effective. To optimize this approach we have developed a series of CARs based on the scFV of broadly neutralizing HIV antibodies targeting four different structural regions of the HIV envelope: the V1/V2 loop, the V3 loop, the CD4 binding site, and the membrane-proximal external region. αHIV-CAR T cells targeting different epitopes were compared and were able to kill > 80% of HIV-infected cells grown in the presence of ART. However, a limitation of αHIV-CAR T cells is that the αHIV-CAR also serves as a receptor for HIV and allows HIV infection of αHIV-CAR T cells. Therefore we disrupted the major co-receptor required for HIV cell entry, CCR5, using a megaTAL nuclease, as a means of protecting the CAR-expressing cells from HIV infection. We used two strategies for achieving these dual modifications in primary human T cells. For both strategies, the CCR5 megaTAL nuclease was delivered by mRNA electroporation, which has previously been shown to induce a high rate of bi-allelic NHEJ-mediated gene disruption. αHIV-CAR expression cassettes were delivered into the host genome via lentiviral vectors (LV), or were targeted to the megaTAL nuclease cleavage site in CCR5 using an adeno-associated virus (AAV) that included CCR5 homology arms. Both strategies resulted in stable expression of the CAR construct and specific activation of CAR+ T cells in the presence of an HIV+ cell line. In the presence of actively replicating virus, CCR5-megaTAL treated CAR+ T cells out-performed CAR+ T cells generated by LV delivery alone as measured by reduction in HIV capsid protein. To enable testing in non-human primates (NHP), we re-optimized the cell-editing protocol with NHP lymphocytes. Primary T cells from pigtail macaques were successfully transfected with CCR5 megaTAL mRNA and achieved a CCR5 disruption rate of 50%. Cells were subsequently transduced with αHIV-CAR LV resulting in ~70% of manipulated cells with αHIV-CAR. Expansion of the cells in vitro resulted in 60-fold expansion over 8 days. CAR+ NHP cells specifically killed HIV infected human cells demonstrating that NHP-derived αHIV-CAR+ T cells retained killing function. In conclusion, it is feasible to construct αHIV-CAR+ T cells that are protected from HIV infection in human and NHP cells, and warrants…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ibarra, G. S. R., Hale, M. R., Sommer, K., Khan, I., Sahni, J., Peterson, C. W., Kiem, H., Jarjour, J., Astrakhan, A., Scharenberg, A. M., Rawlings, D. J., & Wagner, T. A. (2016). 761. Targeted Killing of HIV Infected Cells Using CCR5-Disrupted Anti-HIV-CAR T Cells. Molecular Therapy, 24, S301. https://doi.org/10.1016/s1525-0016(16)33569-9

MLA 9

Ibarra, Guillermo S. Romano, et al. “761. Targeted Killing of HIV Infected Cells Using CCR5-Disrupted Anti-HIV-CAR T Cells.” Molecular Therapy, vol. 24, 2016, p. S301. https://doi.org/10.1016/s1525-0016(16)33569-9.

Chicago

Ibarra, Guillermo S. Romano, Malika R. Hale, Karen Sommer, Iram Khan, Jaya Sahni, Christopher W. Peterson, Hans‐Peter Kiem, et al. 2016. “761. Targeted Killing of HIV Infected Cells Using CCR5-Disrupted Anti-HIV-CAR T Cells.” Molecular Therapy 24: S301. https://doi.org/10.1016/s1525-0016(16)33569-9.

Harvard

Ibarra, G. S. R. et al. (2016) ‘761. Targeted Killing of HIV Infected Cells Using CCR5-Disrupted Anti-HIV-CAR T Cells’, Molecular Therapy, 24, p. S301. doi:10.1016/s1525-0016(16)33569-9.

IEEE

G. S. R. Ibarra et al., “761. Targeted Killing of HIV Infected Cells Using CCR5-Disrupted Anti-HIV-CAR T Cells,” Molecular Therapy, vol. 24, p. S301, 2016, doi: 10.1016/s1525-0016(16)33569-9.

BibTeX

@article{ibarra2016targeted,
  title     = {{761. Targeted Killing of HIV Infected Cells Using CCR5-Disrupted Anti-HIV-CAR T Cells}},
  author    = {Ibarra, Guillermo S. Romano and Hale, Malika R. and Sommer, Karen and Khan, Iram and Sahni, Jaya and Peterson, Christopher W. and Kiem, Hans‐Peter and Jarjour, Jordan and Astrakhan, Alexander and Scharenberg, Andrew M. and Rawlings, David J. and Wagner, Thor A.},
  journal   = {Molecular Therapy},
  year      = {2016},
  volume    = {24},
  pages     = {S301},
  doi       = {10.1016/s1525-0016(16)33569-9},
  url       = {https://doi.org/10.1016/s1525-0016(16)33569-9}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment

  • HIV cure
  • chimeric antigen receptor T cells
  • HIV reservoir
  • broadly neutralizing antibodies
  • HIV reactivation
  • Macaca nemestrina
  • lentiviral vectors
  • AAV gene delivery

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Ibarra, G. S. R., Hale, M. R., Sommer, K., Khan, I., Sahni, J., Peterson, C. W., Kiem, H., Jarjour, J., Astrakhan, A., Scharenberg, A. M., Rawlings, D. J., & Wagner, T. A. (2016). 761. Targeted Killing of HIV Infected Cells Using CCR5-Disrupted Anti-HIV-CAR T Cells. Molecular Therapy, 24, S301. https://doi.org/10.1016/s1525-0016(16)33569-9

How many times has this paper been cited?

2 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Molecular Therapy: sign in and open the PDF from this page.

Who wrote this paper?

Guillermo S. Romano Ibarra, Malika R. Hale, Karen Sommer, Iram Khan, Jaya Sahni, Christopher W. Peterson, Hans‐Peter Kiem, Jordan Jarjour, Alexander Astrakhan, Andrew M. Scharenberg, David J. Rawlings, Thor A. Wagner.

What is the DOI of this paper?

10.1016/s1525-0016(16)33569-9, permanently at https://doi.org/10.1016/s1525-0016(16)33569-9. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.